Tumor Microenvironmental Collagen Signature to Predict Thyroid Cancer Superior Mediastinal Lymph Node Metastasis

Development and Validation of a Tumor Microenvironmental Collagen Signature Based on Multiphoton Imaging to Predict Superior Mediastinal Lymph Node Metastasis of Patients With Thyroid Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06791174

Acronym

TC-CS-SMLNM

Enrollment

181

Registered

2025-01-24

Start date

2024-01-01

Completion date

2024-12-31

Last updated

2025-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid Cancer

Keywords

thyroid cancer, collagen, lymph nodes metastasis, predictive model, multiphoton imaging

Brief summary

About 7-13% thyroid cancer patients have superior mediastinal lymph node metastasis, but its clinical identification is insufficient. Effective and individualized identification strategy need to be studied. Multiphoton imaging can accurately detect extracellular matrix collagen fibers by femtosecond laser. Quantitative features such as morphology and texture features extracted from the multiphoton images, can be used to predict lymph node metastasis of gastrointestinal cancer. Therefore, the investigators speculate that the characteristics of tumor microenvironment (TME) collagen based on multiphoton imaging may be used to predict superior mediastinal lymph node metastasis in thyroid cancer. The aim of this study is to investigate whether the TME collagen signature could predict superior mediastinal lymph nodes metastasis in thyroid cancer. The exposure of this observational cohort study is high TME collagen signature. The main measurement was the area under the receiver operating characteristic (AUROC) curves of collagen signature for predicting superior mediastinal lymph node metastasis.

Detailed description

Retrospective cohorts were enrolled from the Sir Run Run Shaw Hospital of Zhejiang University School of Medicine, The First Affiliated Hospital of Zhengzhou University and Nanfang Hospital from January 2020 to December 2023. Perspective cohort was obtained from all the three centers from January 2024 to July 2024.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Pathologically diagnosed as thyroid cancer * Radical surgery of tumor and simultaneous resection of superior mediastinal lymph nodes

Exclusion criteria

* Reoperation * Under the age of 18 * Combined with thoracopathy, lymphoma or other diseases that may cause mediastinal lymph node enlargement * The superior mediastinal lymph nodes metastasis status was not separately reported * Insufficient pathology section quality * Pregnancy

Design outcomes

Primary

Measure	Time frame	Description
Metastasis status of superior mediastinal lymph nodes	A week after operation generally	Pathology result of superior mediastinal lymph nodes removed on the day of operation.

Countries

China

Outcome results